Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Avacopan on QT/QTc Interval in Healthy Subjects
NCT05988034Phase 1Completed
- Sponsor
- Amgen
- Start
- Nov 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of avacopan in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (3 arms), sponsored by Amgen. Primary endpoint: Change from Baseline in QTcF. Started Nov 2019; status: completed.
02
Drugs
avacopan
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NCT05988034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05988034.